Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -118.95% | 129.97% | 354.26% | 82.81% | -175.64% |
| Total Depreciation and Amortization | -27.83% | -8.73% | 0.00% | 0.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 35.22% |
| Total Other Non-Cash Items | 101.15% | -132.46% | -2,993.44% | -103.75% | 196.91% |
| Change in Net Operating Assets | -108.09% | 202.68% | 164.20% | -198.37% | 714.11% |
| Cash from Operations | -455.67% | 152.09% | 63.47% | 20.31% | -105.67% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -26.33% |
| Total Debt Issued | -- | -- | 100.00% | -102.33% | 267.88% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 100.00% | -100.31% | 1,370.44% |
| Foreign Exchange rate Adjustments | 100.90% | -121,700.00% | -100.27% | 131.66% | -17.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.07% | -38.00% | 62.89% | -133.66% | 6,379.54% |